



EU Policy Symposium 1

Policy & Regulatory Affairs Council

Tuesday, October 20, 08:00–09:30

Session Title

Radioligand Therapy in Europe: Regulation, Readiness and Patient Access

Co-Chairs

Paola Anna Erba (Bergamo, Italy)

Bernhard Sattler (Leipzig, Germany)

Programme

08:00–08:05 Introduction by the Co-Chairs

08:05–08:15 **TBC:** Opening Keynote - The strategic importance of radioligand therapy for Europe's health systems

08:15–08:30 **Arturo Chiti** (Milan, Italy): State of Play - Preparing Healthcare Systems for the RLT Era

08:30–08:45 **Clemens Decristoforo** (Innsbruck, Austria): Regulation and Clinical Practice: Are We Getting the Balance Right?

08:45–09:00 **TBC:** RLT Angels: Building Excellence and Readiness Across Europe

09:00–09:30 Moderated Multi-Stakeholder Panel Discussion - What Must Europe Do to Become RLT-Ready? (All speakers and invited experts): **Anikitos Garofalaki** (Paris, France)

Summary

Radioligand Therapy (RLT) is rapidly becoming a cornerstone of precision oncology, with the potential to transform cancer care across Europe. However, bringing its full clinical and societal value and potential to patients and influencing their paths of treatment requires more than scientific innovation. This symposium will explore the regulatory, organisational, and policy challenges that influence the implementation of RLT in clinical practice and routine patient care. Through perspectives from policymakers, healthcare professionals, and international organisations, the session will examine how Europe can strengthen healthcare system readiness, ensure proportionate and appropriate regulation, and improve timely patient access to RLT. Insights from initiatives such as RLT Angels and a multi-stakeholder panel discussion will identify concrete actions needed to support Europe's transition towards a truly RLT-ready healthcare landscape. The themes align with current discussions on healthcare capacity, regulatory alignment, and access barriers for RLT across Europe.

Educational objectives

- To assess Europe's preparedness for the expected expansion of radioligand therapy.
- To evaluate whether current regulatory frameworks adequately support innovation and clinical implementation.
- To recognise policy and healthcare system actions required to ensure equitable patient access to RLT across Europe.

Key Words

Regulation; Readiness; Access